Skip to main content

Table 3 The association between magnesium-zinc-calcium-vitamin D co-supplementation and pregnancy outcomes

From: The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes

  Placebo group (n = 30) Magnesium-zinc-calcium-vitamin D group (n = 30) P1
Cesarean section (%) 9 (30.0) 4 (13.3) 0.11
Preterm delivery (%) 1 (3.3) 0 (0.0) 0.31
Need to insulin therapy after intervention (%) 2 (6.7) 1 (3.3) 0.55
Pre-eclampsia (%) 3 (10.0) 2 (6.7) 0.64
Polyhydramnios (%) 2 (6.7) 1 (3.3) 0.55
Macrosomia > 4000 g (%) 5 (16.7) 1 (3.3) 0.08
Gestational age (weeks) 39.2 ± 1.1 39.1 ± 1.2 0.90
Newborns’ weight (g) 3346.3 ± 411.1 3089.8 ± 519.9 0.05
Newborns’ length (cm) 50.0 ± 1.4 49.2 ± 3.6 0.28
Newborns’ head circumference (cm) 35.2 ± 1.7 34.4 ± 3.0 0.20
1- min Apgar score 8.8 ± 0.4 8.9 ± 0.3 0.45
5- min Apgar score 9.8 ± 0.4 9.9 ± 0.3 0.45
Newborns’ hyperbilirubinemia (%) 12 (40.0) 8 (26.7) 0.27
Newborns’ hospitalization (%) 12 (40.0) 8 (26.7) 0.27
  1. Values are means± SDs for continuous measures and are number (%) for dichotomous variables
  2. 1Obtained from independent t-test
  3. Obtained from Pearson Chi-square test